Boehringer Ingelheim (BI) and Bioharmony Therapeutics Collaborates to Develop Bacteriophage Lysins
Shots:
- BI to get rights to develop and commercialize bacteriophage lysins using Bioharmony ‘s technology for multi-drug resistant (MDR) Acinetobacter infections caused by Acinetobacter baumannii
- The focus of the collaboration is to develop anti-microbial therapies against multi-drug resistant bacterial infections
- Lysins are enzymes made of bacteriophages involved in breaching the bacterial cell wall in seconds- further killing the targeted bacteria
Ref: Businesswire | Image: BigChem
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com